Hanmi's oncology segment focuses on the research, development, and commercialization of innovative cancer therapies. This includes the development of novel bispecific antibodies based on the Pentambody™ platform, a unique technology for creating multi-specific antibodies. The segment's R&D activities involve preclinical studies, clinical trials, and regulatory submissions for various cancer types. The company is also collaborating with partners on co-development projects, including immuno-oncology bispecific antibodies. The segment aims to improve patient outcomes by providing targeted therapies with enhanced efficacy and reduced side effects, addressing unmet medical needs in the oncology market. Future opportunities include expanding the pipeline with new drug candidates and exploring partnerships to accelerate development and market access.

This segment is dedicated to the development of treatments for metabolic disorders, with a primary focus on diabetes and obesity. Hanmi's research and development efforts include the creation of novel drugs, such as HM17321, a promising obesity treatment. The company utilizes advanced technologies and methodologies to discover and develop these drugs, including long-acting platforms and innovative drug delivery systems. The segment aims to address the growing global burden of metabolic diseases by providing effective and safe therapies. This involves conducting clinical trials, securing regulatory approvals, and establishing partnerships for commercialization. The market positioning is strengthened by the company's focus on innovation and its ability to develop drugs with unique mechanisms of action. Future growth will be driven by the increasing prevalence of metabolic diseases and the demand for more effective treatments.

Hanmi's CDMO segment provides comprehensive services for pharmaceutical development and manufacturing. This includes formulation development, process optimization, clinical trial material manufacturing, and commercial manufacturing. The segment leverages its expertise in various dosage forms, including oral solids, injectables, and biologics. The CDMO segment supports the development of new drugs by providing high-quality manufacturing services and ensuring compliance with regulatory standards. This segment is positioned to capitalize on the growing demand for outsourced pharmaceutical manufacturing services. The company's focus on innovation and its ability to provide integrated solutions gives it a competitive advantage. Future opportunities include expanding its manufacturing capacity, entering new markets, and forming strategic partnerships with other pharmaceutical companies.